A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs IFX 1 (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Acronyms SHINE
  • Sponsors InflaRx
  • Most Recent Events

    • 08 Mar 2018 According to an InflaRx media release, company today announced that the first patient has been enrolled in this study.
    • 08 Mar 2018 Status changed from planning to recruiting, according to an InflaRx media release.
    • 09 Jan 2018 According to an InflaRx media release, Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis at the ATTIKON University Hospital in Athens, Greece is the principal investigator for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top